North America’s medical devices industry saw a rise of 5.43% in deal activity during April 2021, when compared with the last 12-month average, led by $5bn acquisition of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 97 medical devices industry deals worth $9.6bn were announced for the region in April 2021, against the 12-month average of 92 deals.

Of all the deal types, venture financing saw most activity in April 2021 with 60 transactions, representing a 61.9% share for the region.

In second place was M&A with 25 deals, followed by private equity deals with 12 transactions, respectively capturing a 25.8% and 12.4% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $7.41bn, while venture financing and private equity deals totalled $1.43bn and $727.8m, respectively.

North America medical devices industry deals in April 2021: Top deals

The top five medical devices deals accounted for 79.7% of the overall value during April 2021.

The combined value of the top five medical devices deals stood at $7.62bn, against the overall value of $9.6bn recorded for the month.

The top five medical devices industry deals of April 2021 tracked by GlobalData were:

1) The $5bn merger of CA Healthcare Acquisition and LumiraDx

2) The $1.8bn acquisition deal with Luminex by DiaSorin

3) The Carlyle Group’s $435m private equity deal with Unchained Labs

4) The $200m acquisition of Genosity by InVitae

5) Mountain Crest AcquisitionII’s acquisition of Better Therapeutics for $187m.